Teoxane Showcases Swiss Innovation at the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting

Teoxane Showcases Swiss Innovation at the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting

November 2025, New York, NY – Teoxane, the Swiss pioneer in aesthetic medicine and hyaluronic acid innovation, participated in the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting, held in New York from November 13th to 16th.

This annual congress brought together dermatologic surgeons, researchers, and aesthetic experts from around the world to exchange insights on scientific advances and evolving best practices in dermatologic and aesthetic medicine.

Teoxane was present to reaffirm its commitment to scientific excellence, innovation, and Swiss quality. Throughout the meeting, the brand showcased its latest dermocosmetics collection and highlighted the resilience, precision, and performance of its RHA technology, which continues to shape both topical skincare and HA-based solutions.

Can Ongen, Chief Operating Officer at Teoxane SA and President of Teoxane USA, and Carine Blondin, Global Head of Dermocosmetics, attended the event to participate in key discussions focused on the future of dermocosmetic innovation.

“ASDS remains an important moment to connect with leading dermatologists and aesthetic professionals. These exchanges support the industry’s progress and strengthen Teoxane’s commitment to developing safe, effective HA-based solutions for patients in the U.S. and globally.” - Can Ongen, COO and President of Teoxane USA

“Teoxane’s dermocosmetic innovations are grounded in our Swiss heritage of scientific precision. The same RHA technology designed for our HA fillers has been adapted for skincare, bringing advanced aesthetic science to topical solutions. ASDS is a valuable opportunity to demonstrate this evolution.” - Carine Blondin, Global Head of Dermocosmetics